Lunai Bioworks Files For Non Timely 10-K With U.S. SEC; Anticipates Reporting A Net Loss For The Fiscal Year Ended June 30, 2026 Of ~$3.2M

Lunai Bioworks has filed a non-timely 10-K with the U.S. SEC, projecting a net loss of approximately $3.2 million for the fiscal year ended June 30, 2026, a significant reduction from a net loss of about $178.0 million in the prior fiscal year. This decrease is mainly due to the absence of a $170.4 million goodwill impairment charge from fiscal 2025, along with reduced general and administrative expenses and a gain from the deconsolidation of GEDi Cube B.V. However, this is partially offset by losses related to debt restructuring and asset impairments.